Epidemiological trends and financial outcomes in radical prostatectomy among Medicare beneficiaries, 1991 to 1993.
OBJECTIVE
We define epidemiological trends in radical prostatectomy among Medicare beneficiaries in the United States, describe related financial reimbursement to hospitals and physicians, and determine how many men received adjuvant therapy with androgen ablation or pelvic irradiation from 1991 to 1993.


METHODS
We examined radical prostatectomy claims from a national 5% simple random sample (688,000 men) of 1991, 1992 and 1993 data on Medicare beneficiaries from the Health Care Financing Administration. We determined rates of radical prostatectomies among patients stratified by age, race and geographical region, and measured the fraction of men who had claims submitted for postoperative therapies for prostate cancer. We also collected financial information for Medicare parts A and B to estimate federal government economic burden from radical prostatectomy in this population.


RESULTS
Among the 5,016 patients identified with Medicare claims for radical prostatectomy during 1991 to 1993 the rate peaked at 284/100,000 men in 1992 before declining the next year. For the youngest Medicare beneficiaries the rate increased 233% from 1991 to 1992 and 156% from 1992 to 1993. White men had a higher rate than nonwhite men in all 3 years but only in nonwhite men did the rate continue to rise during the study period. Geographical variations greater than 2-fold were noted. Total Medicare expenditures for radical prostatectomy were $194.2 million in 1991, $277.8 million in 1992 and $230.8 million in 1993. During 1991 to 1993 hospitals received more than three-fourths of total Medicare payments for radical prostatectomy, while physicians received less than one-fourth. More than 23% of men undergoing radical prostatectomy received subsequent therapy with gonadotropin releasing hormone agonists, bilateral orchiectomy and/or pelvic irradiation within 3 years of radical prostatectomy.


CONCLUSIONS
Radical prostatectomy represents a significant burden on the federal health care dollar and does not appear to be as definitively curative as expected.
Litwin
M S
MS
Department of Urology, University of California, Los Angeles, USA.
Pasta
D J
DJ
Stoddard
M L
ML
Henning
J M
JM
Carroll
P R
PR
D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D014487:Centers for Medicare and Medicaid Services, U.S.; D017024:Chemotherapy, Adjuvant; D004469:Economics, Hospital / Q000706:statistics & numerical data; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D005102:Health Expenditures; D006801:Humans; D008297:Male; D006278:Medicare / Q000191:economics / Q000706:statistics & numerical data*; D016344:Medicare Part A / Q000191:economics / Q000706:statistics & numerical data; D016345:Medicare Part B / Q000191:economics / Q000706:statistics & numerical data; D009919:Orchiectomy / Q000191:economics / Q000706:statistics & numerical data; D010820:Physicians / Q000191:economics; D011468:Prostatectomy / Q000191:economics / Q000706:statistics & numerical data*; D018714:Radiotherapy, Adjuvant; D012051:Reimbursement Mechanisms / Q000191:economics / Q000706:statistics & numerical data; D014481:United States / Q000453:epidemiology; D044465:White People
D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D007987:Gonadotropin-Releasing Hormone